New Delhi: 2-deoxy-D-glucose (2-DG), the anti-COVID-19 drug that
has been developed by Defence Research and Development Organization (DRDO)
and been given an emergency use nod by Drugs Controller General of India’s (DCGI),
was first studied by Patanjali researchers, claimed Acharya Balkrishna.
